Results 141 to 150 of about 2,429 (159)
Spinocerebellar ataxia type 6 (SCA6): Clinical pilot trial with gabapentin [PDF]
The clinical effect of the GABAergic drug gabapentin was evaluated in 11 patients with spinocerebellar ataxia type 6 (SCA6). The total period of gabapentin treatment was 4 weeks, and outcome measures were determined with the International Cooperative ...
Katsuya Nakamura
exaly +3 more sources
Haplotype study in Dutch SCA3 and SCA6 families: evidence for common founder mutations
This pilot study was initiated to show the existence of founder effects in the Dutch autosomal dominant cerebellar ataxia (ADCA) population. The ADCAs comprise a clinically heterogeneous group of neurodegenerative disorders and the estimated prevalence ...
Dineke Verbeek
exaly +2 more sources
Spinocerebellar ataxia type 6 (SCA6) is a common cause of dominantly inherited ataxia due to an expansion of the CAG repeat in the CACNA1A gene. Affected individuals from the same population share a common haplotype, raising the possibility that most ...
Laura Bannach Jardim +2 more
exaly +2 more sources
Second Cistron in CACNA1A Gene Encodes a Transcription Factor Mediating Cerebellar Development and SCA6 [PDF]
SummaryThe CACNA1A gene, encoding the voltage-gated calcium channel subunit α1A, is involved in pre- and postsynaptic Ca2+ signaling, gene expression, and several genetic neurological disorders.
Christian Hansel +2 more
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Meiotic instability of the CAG repeats in the SCA6/CACNA1A gene in two Japanese SCA6 families
Journal of the Neurological Sciences, 2001Yoshihisa Takiyama +2 more
exaly
Episodic ataxia and SCA6 within the same family due to the D302N CACNA1A gene mutation
Journal of the Neurological Sciences, 2016Alessandro Mauro +2 more
exaly
Neuropathological and molecular studies of spinocerebellar ataxia type 6 (SCA6)
Acta Neuropathologica, 1998Ichiro Yabe +2 more
exaly

